ACE Question

Abstract

Article| May 2022 ACE Question ASA Monitor May 2022, Vol. 86, 16. https://doi.org/10.1097/01.ASM.0000830808.15004.67 Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn MailTo Cite Icon Cite Get Permissions Search Site Citation ACE Question. ASA Monitor 2022; 86:16 doi: https://doi.org/10.1097/01.ASM.0000830808.15004.67 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll PublicationsASA Monitor Search Advanced Search Topics: anesthesiology continuing education (ace) Due to national drug shortages, your facility is unable to obtain bupivacaine. You are planning a peripheral nerve block, and the only preservative-free local anesthetic available is 1.5% mepivacaine. What would be the MOST likely result of using mepivacaine in comparison to bupivacaine? Mepivacaine is an intermediate-potency amide local anesthetic that can be used for peripheral nerve blockade. It is commonly available in a 1.5% concentration. When compared to longer-duration agents such as bupivacaine, the following differences are commonly noted: The addition of epinephrine (1:200,000) will prolong the action of local anesthetics administered for a peripheral nerve block. The extent of this prolongation is greater with intermediate-acting agents such as mepivacaine than with longer-acting agents such as bupivacaine. Anesthesiology Continuing Education (ACE) is a self-study CME program that covers established medical knowledge in the field of anesthesiology. ACE can help fulfill the CME requirements of MOCA®. To learn... You do not currently have access to this content.